With 32 high-risk innovative medical devices approved in 2021, the picture for companies trying to bring new products to the US market is not as bad as it appeared six months ago. By the end of the year, the overall number of approvals was only one shy of 2020’s total.
In terms of review times, however, the agency has slowed down.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,